N/A N=33 Rilonacept (Arcalyst ®) in the Treatment of Subacromial Bursitis
Subacromial Bursitis
Primary: Improvement in Shoulder Function — 15.92; 38.52 units on a scale — p=0.004
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=35 Studying Amphetamine Withdrawal in Humans
Methamphetamine Dependence
Primary: Measure of Methamphetamine Withdrawal — 3.7283; 10.056 units on a scale
Phase 3 N=554 A Study of the Safety and Efficacy of a New Treatment for Diabetic Macular Edema
Diabetic Macular Edema
Primary: Percentage of Patients With a Best Corrected Visual Acuity (BCVA) Improvement of ≥15 Letters From Baseline in the Study Eye — 22.3; 18.2; 10.8 Percentage of Patients
Phase 4 N=61 Effect of Nebulized Budesonide and Oral Corticosteroids on Wheezing Episode Relapse in Children
Asthma
Primary: Wheezing/Asthma/Bronchospasm Relapse Rate — 8.7; 4.0 percentage of cases of asthma relapse
Phase 3 N=416 Continued Efficacy and Safety of Zoledronic Acid (q 4 Wks vs. q 12 Wks) in the 2nd Year of Treatment in Patients With Bone Metastases From Breast Cancer
Breast Cancer
Primary: Proportion of Patients Who Experienced at Least One Skeletal Related Event (SRE) — 22; 23.2 Percentage of participants
Phase 3 N=1,380 Study of Telcagepant (MK-0974) in Participants With Moderate to Severe Acute Migraine With or Without Aura (MK-0974-011)
Migraine
Primary: Number of Participants With Pain Freedom (PF) at 2 Hours Post-Dose — 56; 89; 101; 29 Participants — p=<0.001
N/A N=205 A Study to Determine the Difference in Low Contact Stress (LCS) Duofix Versus Low LCS Porocoat Knee Systems
Osteoarthritis
Primary: Difference in the Mean VAS Pain Score Between Subjects Receiving LCS Complete Duofix™ and Porocoat® Knee Systems at 12 Months. — 2.51; 2.53 units on a scale — p=0.9478
Phase 4 N=210 A Study of CellCept (Mycophenolate Mofetil) Combined With Tacrolimus and Corticosteroids in Kidney Transplant Patients.
Kidney Transplantation
Primary: Chronic Allograft Damage Index (CADI) Score at Month 12 After Transplantation — 1.82; 2.13 score on a scale — p=0.0813
Phase 3 N=107 A Study With Tocilizumab [RoActemra/Actemra] Monotherapy or in Combination With Methotrexate in Patients With Rheumatoid Arthritis (PICTURE)
Rheumatoid Arthritis
Primary: Percentage of Participants Achieving Disease Activity Score 28 (DAS28) Low Disease Activity — 27.59; 18.42; 34.48; 40.79 percentage of participants
N/A N=24 Open-Label Study for Shoulder Dislocation Using MG-1
Shoulder Dislocation
Primary: Surgery Success — 23 participants
N/A N=109 Anesthetic Effect of Lidocaine/Epinephrine Solution Delivered Via Iontophoresis to External Auditory Apparatus
Acute Otitis Media · Chronic Otitis Media · Recurrent Acute Otitis Media
Primary: Proportion of Subjects Who Achieved Anesthesia Effectiveness Per Investigator Assessment — 89.9 percentage of subjects
Phase 2 N=123 Mindfulness Meditation for Health
Alcohol Dependence
Primary: Percent Heavy Drinking Days — 3.8; 3.0 percentage of heavy drinking days
Phase 3 N=34 The Use of Etanercept Enbrel as Sole Treatment for Grade I Acute Graft Versus Host Disease
Acute Graft Versus Host Disease
Primary: The Percentage of Patients Who Progress Within 28 Days of Initiation of Etanercept Treatment — 29 percentage of patients
Phase 2 N=75 Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
Adenocarcinoma of the Gastroesophageal Junction · Diffuse Gastric Adenocarcinoma · Gastric Intestinal Type Adenocarcinoma
Primary: Overall Survival (OS) — 5 months
Phase 2 N=253 Safety and Efficacy of a New Treatment in Combination With Laser for Diabetic Macular Edema
Diabetic Macular Edema
Primary: Percentage of Patients With at Least 10 Letters of Improvement in Best Corrected Visual Acuity (BCVA) From Baseline in the Study Eye — 27.8; 23.6 Percentage of Patients